Fatma E El-Khouly
Overview
Explore the profile of Fatma E El-Khouly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiese M, Pohlmeier B, Kubiak K, El-Khouly F, Sitte M, Carcaboso A, et al.
J Tradit Complement Med
. 2024 Jan;
14(1):101-108.
PMID: 38223806
Background And Aim: Pediatric high-grade gliomas (pedHGG) comprise a very poor prognosis. Thus, parents of affected children are increasingly resorting to complementary and alternative medicine (CAM), among those Boswellia extracts....
2.
El-Khouly F, Haumann R, Breur M, Veldhuijzen van Zanten S, Kaspers G, Hendrikse N, et al.
Free Neuropathol
. 2023 Jun;
2.
PMID: 37284626
Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a median overall survival of eleven months. Lack of chemotherapy efficacy may be related to an intact blood-brain barrier...
3.
El-Khouly F, Veldhuijzen van Zanten S, Jansen M, Bakker D, Sanchez Aliaga E, Hendrikse N, et al.
J Neurooncol
. 2021 May;
153(2):263-271.
PMID: 33963476
Introduction: This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse...
4.
El-Khouly F, Adil S, Wiese M, Hulleman E, Hendrikse N, Kaspers G, et al.
Pediatr Blood Cancer
. 2021 May;
68(9):e29061.
PMID: 33942498
Introduction: Diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive childhood brainstem malignancy with a 2-year survival rate of <10%. This international survey study aims to evaluate the use...
5.
El-Khouly F, Veldhuijzen van Zanten S, Santa-Maria Lopez V, Hendrikse N, Kaspers G, Loizos G, et al.
J Neurooncol
. 2019 Sep;
145(1):177-184.
PMID: 31522324
Introduction: Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically, and molecularly defined malignancy of the brainstem with a median overall survival of approximately 11 months. Our aim is...
6.
El-Khouly F, van Vuurden D, Stroink T, Hulleman E, Kaspers G, Hendrikse N, et al.
Front Oncol
. 2017 Nov;
7:254.
PMID: 29164054
Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic chemotherapy may be attributed...
7.
Veldhuijzen van Zanten S, El-Khouly F, Jansen M, Bakker D, Sanchez Aliaga E, Haasbeek C, et al.
J Neurooncol
. 2017 Oct;
136(1):219-220.
PMID: 29063425
In Table 2 of the original publication, there were errors in the baseline scores for the PedsQL TM 3.0 Cancer Module questionnaire, so a corrected version of Table 2 is...
8.
Veldhuijzen van Zanten S, El-Khouly F, Jansen M, Bakker D, Sanchez Aliaga E, Haasbeek C, et al.
J Neurooncol
. 2017 Jul;
135(2):307-315.
PMID: 28748343
The purpose of this phase I/II, open-label, single-arm trial is to investigate the safety, tolerability, maximum tolerated dose and preliminary efficacy of the potential radiosensitizer gemcitabine, administered concomitantly to radiotherapy,...